122

Magnesium Glycerophosphate Tablets

Prescriber Criteria: Consultant Gastroenterologist
Consultant Geriatrician
Consultant Haematologist
Consultant Nephrologist
Consultant Oncologist
Consultant Paediatrician
Consultant Palliative Care

Outpatient and Inpatient use:

1. Chronic Kidney Disease
2. Chronic Liver Disease
3. Inborn Errors of Metabolism
4. Malignant Diseases
5. Secondary Immunodeficiency Disorders

Prevention and treatment of hypomagnesaemia:

- in patients on immunosuppressant medications
- secondary to treatment with cytotoxic drugs in paediatric patients
- in patients with electrolyte imbalance secondary to one of the above-mentioned conditions
- in transplant patients

Duration of approval:
2 years